Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RMP-A03
- Development stage
- Phase 2
- Lead developer
- Suzhou Ruiming New Drug Research & Development
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
RMP-A03 is a small molecule chemical drug developed for the treatment of pterygium, an ocular surface disease characterized by abnormal fibrovascular growth on the conjunctiva. The drug is being evaluated as an ocular suspension and has completed Phase 2 clinical trials assessing its safety and efficacy in patients with pterygium. The precise mechanism of action for RMP-A03 remains unknown, and it does not represent a novel mechanism of action. The developer and active organization behind this compound is Suzhou Ruiming New Drug Research & Development Co., Ltd., also referred to as Suzhou Raymon Pharmaceuticals Company, Ltd.[1][2][3]
- Other names
- nintedanib ophthalmic
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)Tyrosine kinase
Beyond the preview
Go deeper on RMP-A03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RMP-A03.